Definitions and epidemiology of Candida species not susceptible to echinocandins

Current Fungal Infection Reports

Volumn 5, Issue 3, 2011, Pages 120-127

  Pfaller, Michael A ^a   Diekema, Daniel J ^a   Castanheira, Mariana ^b   Jones, Ronald N ^b  

^a UNIVERSITY OF IOWA   (United States)

^b JMI LABORATORIES   (United States)

Author keywords

Anidulafungin; Antifungal agents; Candida; Caspofungin; Clinical breakpoint; Echinocandins; Epidemiology; In vitro testing; MIC; Micafungin; Resistance; Susceptibility

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; MICAFUNGIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; EPIDEMIC; FKS GENE; FUNGAL DETECTION; FUNGAL GENE; FUNGAL STRAIN; GENE MUTATION; HUMAN; KLUYVEROMYCES MARXIANUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA GUILLIERMONDII; WILD TYPE;

EID: 80755135448     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-011-0053-y     Document Type: Article

References (79)

1. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy. 2007;27:369-88. (Pubitemid 46327905)
2. Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis. 2006;42:1171-8.
3. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis. 2003;36:1445-57.
4. Dodds-Ashley ES, Lewis R, Lewis JS, et al. Pharmacology of systemic antifungal agents. Clin Infect Dis. 2006;43:S28-39. (Pubitemid 44078894)
5. Messer SA, Diekema DJ, Boyken L, et al. Activities of micafungin against 315 invasive clinical isolates of fluconazoleresistant Candida spp. J Clin Microbiol. 2006;44:324-6. (Pubitemid 43222217)
6. Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J Clin Microbiol. 2006;44:1782-7. (Pubitemid 43726269)
7. Pfaller MA. Anidulafungin: An echinocandin antifungal. Expert Opin Investig Drugs. 2004;13:1183-97. (Pubitemid 39242741)
8. Vazquez JA. Anidulafungin: a new echinocandin with a novel profile. Clin Ther. 2005;27:657-73. (Pubitemid 41583515)
9. Zaas AK, Alexander BD. Echinocandins: role in antifungal therapy, 2005. Expert Opin Pharmacother. 2005;6:1657-68. (Pubitemid 41167673)
10. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis. 2004;39:842-9. (Pubitemid 39244300)
11. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369:1519-27. (Pubitemid 46670281)
12. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020-9. (Pubitemid 35461658)
13. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis. 2005;24:654-61. (Pubitemid 41667052)
14. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45:883-93. (Pubitemid 47580382)
15. Astellas Pharma: Mycamine. Available at http://www.astellas.us/ therapeutic/product/mycamine.html. Accessed March 9, 2011.
16. Merck and Co.: Cancidas. Available at http://www.merck.com/product/usa/ pi-circulars/c/cancidas/cancidas-pi.pdf. Accessed March 9, 2011.
17. Pfizer Inc.: Eraxis. Available at http://www.pfizer.com/files/prod ucts/uspi-eraxis.pdf. Accessed March 9, 2011.
18. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-35.
19. Bal AM. The echinocandins: three useful choices or three too many? Int J Antimicrob Agents. 2010;35:13-8.
20. Glockner A, Steinbach A, Vehreschild JJ, et al. Treatment of invasive candidiasis with echinocandins. Mycoses. 2008;52:476-86.
21. Lichtenstein C, Nguyen TH, Schemmer P, et al. Efficacy of caspofungin in invasive candidiasis and candidemia-de-escalation strategy. Mycoses. 2008;51:S35-46.
22. Ortega M, Marco F, Soriano A, et al. Candida spp. bloodstream infection: influence of antifungal treatment on outcome. J Antimicrob Chemother. 2010;65:562-8.
23. Sipsas NV, Lewis RE, Tarrand J, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer. 2009;115:4745-52.
24. Sipsas NV, Lewis RE, Raad II, Kontoyiannis DP. Monotherapy with caspofungin for candidaemia in adult patients with cancer: a retrospective, single institution study. Int J Antimicrob Agents. 2009;34:95-8.
25. Zaas AK, Dodds Ashley ES, Alexander BD, et al. Caspofungin for invasive candidiasis at a tertiary care medical center. Am J Med 2006; 119: 993 e1-6.
26. Baixench MT, Aoun N, Desnos-Ollivier M, et al. Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother. 2007;59:1076-83. (Pubitemid 47073317)
27. Ghannoum MA, Chen A, Buhari M, et al. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit. Clin Microbiol Infect. 2009;15:274-9.
28. Kofteridis DP, Lewis RE, Kontoyiannis DP. Caspofungin-nonsusceptible Candida isolates in cancer patients. J Antimicrob Chemother. 2010;65:293-5.
29. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat. 2007;10:121-30. (Pubitemid 47031054)
30. Perlin DS. Antifungal drug resistance: do molecular methods provide a way forward? Curr Opin Infect Dis. 2009;22:568-73. This article provides useful insights concerning the molecular characterization of fungal resistance mechanisms.
31. Pfeiffer CD, Garcia-Effron G, Zaas AK, et al. Breakthrough invasive candidiasis onmicafungin. J ClinMicrobiol. 2010;48:2373
32. This is an important observational study of echinocandin breakthrough infections.
33. Sun HY, Singh N. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int J Antimicrob Agents. 2010;35:211-8. This is a very comprehensive review of echinocandin breakthrough infections.
34. Arendrup MC, Garcia-Effron G, Lass-Florl C, et al. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother. 2010;54:426-39. This article demonstrates the ability of several in vitro testing methods to detect fks mutations.
35. Cleary JD, Garcia-Effron G, Chapman SW, et al. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother. 2008;52:2263-5. (Pubitemid 351758575)
36. Chapeland-Leclerc F, Hennequin C, Papon N, et al. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob Agents Chemother. 2010;54:1360-2.
37. Garcia-Effron G, Lee S, Park S, et al. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1, 3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother. 2009;53:3690-9.
38. Garcia-Effron G, Park S, Perlin DS. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother. 2009;53:112-22.
39. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol. 2008;46:150-6.
40. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretiveMIC breakpoints. J ClinMicrobiol. 2008;46:2620-9.
41. Pfaller MA, Boyken L, Hollis RJ, et al. Wild-type MIC distributions and epidemiological cutoff values (ECVs) for the echinocandins and Candida spp. J Clin Microbiol. 2010;48:52-6. This is the first description of ECVs for echinocandins.
42. Pfaller MA, Castanheira M, Diekema DJ, et al. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J Clin Microbiol. 2010;48:1592-9. This paper presents an important step towards harmonization between CLSI and EUCAST antifungal test methods.
43. Wiederhold NP, Grabinski JL, Garcia-Effron G, et al. Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. Antimicrob Agents Chemother. 2008;52:4145-8.
44. Zimbeck AJ, Iqbal N, Ahlquist AM, et al. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother. 2010;54:5042-7. This is the first populationbased assessment of the frequency of fks mutations among clinical isolates of C. glabrata.
45. Clinical and Laboratory Standards Institute. M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts. 3rd ed. Wayne: CLSI; 2008a.
46. Clinical and Laboratory Standards Institute. M27-S3. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd informational supplement. Wayne: CLSI; 2008b.
47. Clinical and Laboratory Standards Institute. M44-A2. Method for antifungal disk diffusion susceptibility testing of yeasts: approved standard. Wayne: CLSI; 2008c.
48. Clinical and Laboratory Standards Institute. M44-S2. Zone diameter interpretive standards, corresponding minimal inhibitory concentration (MIC) interpretive breakpoints and quality control limits for antifungal disk diffusion susceptibility testing of yeasts: informational supplement. Wayne: CLSI; 2007.
49. Arendrup MC, Garcia-Effron G, Buzina W, et al. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother. 2009;53:1185-93.
50. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12, 052 fungal isolates: review of the literature. Rev Iberoam Micol. 2003;20:121-36. (Pubitemid 38724618)
51. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2, 000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother. 2003;47:3149-54. (Pubitemid 37229571)
52. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro activities of anidulafungin against more than 2, 500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol. 2005;43:5425-7. (Pubitemid 41612308)
53. Pfaller MA, Boyken L, Hollis RJ, et al. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J Clin Microbiol. 2006;44:3533-8. (Pubitemid 46768811)
54. Pfaller MA, Moet GJ, Messer SA, et al. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol. 2011;49:396-9.
55. Pfaller M, Boyken L, Hollis R, et al. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin. J Clin Microbiol. 2011;49:624-9.
56. Pfaller MA, Messer SA, Moet GJ, et al. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J Antimicrob Agents 2011; In press.
57. Pfaller MA, Moet GJ, Messer SA, et al. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother. 2011;55:561-6.
58. Pfaller MA, Castanheira M, Messer SA, et al. Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009). Diagn Microbiol Infect Dis. 2010;68:278-83.
59. Desnos-Ollivier M, Bretagne S, Raoux D, et al. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob Agents Chemother. 2008;52:3092-8.
60. Garcia-Effron G, Katiyar SK, Park S, et al. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother. 2008;52:2305-12. (Pubitemid 351915657)
61. Garcia-Effron G, Kontoyiannis DP, Lewis RE, et al. Caspofunginresistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother. 2008;52:4181-813.
62. Garcia-Effron G, Chua DJ, Tomada JR, et al. Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob Agents Chemother. 2010;54:2225-7.
63. Laverdiere M, Lalonde RG, Baril JG, et al. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother. 2006;57:705-8.
64. Park DR. The microbiology of ventilator-associated pneumonia. Respir Care. 2005;50:742-63. (Pubitemid 46179541)
65. Dodgson KJ, Dodgson AR, Pujol D, et al. Caspofungin resistant C. glabrata. Clin Microbiol Infect. 2005;11:364.
66. Miller CD, Lomaestro BW, Park S, et al. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy. 2006;26:877-80. (Pubitemid 43807639)
67. Hakki M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother. 2006;50:2522-4. (Pubitemid 43993195)
68. Kahn JN, Garcia-Effron G, Hsu MJ, et al. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother. 2007;51:1876-8. (Pubitemid 46744179)
69. Thompson III GR, Wiederhold NP, Vallor AC, et al. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother. 2008;52:3783-5.
70. Turnidge J, Kahlmeter G, Kronvall G. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect. 2006;12:418-25.
71. Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev. 2007;20:391-408. (Pubitemid 47175010)
72. Arendrup MC, Kahlmeter G, Rodriguez-Tudela JL, et al. Breakpoints for susceptibility testing should not divide wild-type distributions of important target species. Antimicrob Agents Chemother. 2009;53:1628-9.
73. Kahlmeter G, Brown DF, Goldstein FW, et al. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother. 2003;52:145-8. (Pubitemid 36986868)
74. Kahlmeter G, Brown DFJ. Harmonization of antimicrobial breakpoints in Europe-Can it be achieved? Clin Microbiol Newsl. 2004;26:187-92. (Pubitemid 40142649)
75. Rodriguez-Tudela JL, Arendrup MC, Barchiesi F, et al. EUCAST definitive document EDef 7.1: Method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect. 2008;14:398-405. (Pubitemid 351356536)
76. Simjee S, Silley P, Werling HO, et al. Potential confusion regarding the term 'resistance' in epidemiological surveys. J Antimicrob Chemother. 2008;61:228-9.
77. Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at speciesspecific interpretive criteria. Drug resist Updat 2011 Feb 23 (Epub ahead of print). This is the most recent description of the development of CBPs for the echinocandins.
78. Andes D, Diekema DJ, Pfaller MA, et al. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother. 2008;52:539-50. (Pubitemid 351170826)
79. Andes DR, Diekema DJ, Pfaller MA, et al. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother. 2008;52:3497-503.